Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective α1-adrenoceptor antagonist that preferentially binds to α1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Treatment of signs and symptoms of benign prostatic hyperplasia (BPH).
* Off-label: Medical expulsive therapy (MET) for ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day. If no response after 2–4 weeks, the dose may be increased to 0.8 mg daily.
* **Maximum Dose:** 0.8 mg daily.
## Pediatric Dosing
* **Status:** Not FDA-approved for pediatric use.
* **Off-label/Specialty Use:** Used sparingly in pediatric urology for voiding dysfunction under specialist supervision. Dosing is highly variable and weight-based; refer strictly to local pediatric urology protocols/institutional guidelines.
## Dose Adjustments
* **Renal Impairment:** No initial dosage adjustment required for mild to moderate impairment. Use caution in severe renal impairment (CrCl <10 mL/min); data is limited.
* **Hepatic Impairment:** Not recommended for use in patients with severe hepatic impairment (Child-Pugh score >9).
## Contraindications
* Known hypersensitivity to tamsulosin or any component of the product.
* History of angioedema.
## Adverse Effects
* **Common:** Dizziness, headache, abnormal ejaculation (retrograde), rhinitis, orthostatic hypotension.
* **Serious:** Severe hypotension, syncope, Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, priapism (rare).
## Key Drug Interactions
* **Strong CYP3A4/2D6 Inhibitors:** (e.g., ketoconazole, clarithromycin, paroxetine) May significantly increase tamsulosin plasma concentrations; reduce dose or avoid concurrent use.
* **PDE5 Inhibitors:** (e.g., sildenafil, tadalafil) May lead to additive blood pressure lowering effects; initiate PDE5 inhibitors at the lowest possible dose.
* **Antihypertensives:** Potential for additive symptomatic orthostatic hypotension.
## Monitoring
* Monitor blood pressure during dose initiation or adjustment.
* Assess symptom improvement (e.g., AUA Symptom Score) periodically.
* Monitor for signs of cardiovascular intolerance (dizziness, tachycardia).
## Clinical Pearls
* **Administration:** Must be taken 30 minutes after the same meal daily to ensure consistent bioavailability; fasting administration increases peak plasma concentration and risk of adverse effects.
* **IFIS Risk:** Tamsulosin may cause Intraoperative Floppy Iris Syndrome during cataract surgery. Patients should inform their ophthalmologist of current or prior use before surgery.
* **Syncope:** First-dose effect is uncommon but possible; advise patients to rise slowly from a sitting/lying position.
* **Pillar of Therapy:** Does not reduce prostate size; it addresses symptoms only.
***
*Disclaimer: This information is for educational purposes. Drug information, protocols, and safety guidelines are subject to change. Always verify current prescribing information, institutional protocols, and specific clinical settings before administering medication.*
